Related Experiment Video
Updated: Oct 16, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Anecdote Increases Patient Willingness to Take a Biologic Medication for Psoriasis
Matthew C Johnson1, Elias Oussedik1, William Wei-Ting Huang1
1Drs. Johnson, Oussedik, Huang, and Feldman are from the Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina. Dr. Feldman also is from the Departments of Pathology and Social Sciences & Health Policy. Dr. Oussedik also is from the Faculty of Medicine, McGill University, Montreal, Quebec, Canada. Dr. Kammrath is from the Department of Psychology, Wake Forest University, Winston-Salem.
Abstract:
Patients often are apprehensive about starting biologic medications for their psoriasis. Typical fears include anxiety regarding possible side effects and reluctance in accepting their proven efficacy. In this study, we aimed to evaluate patients' willingness to take a biologic medication for their psoriasis if presented with clinical trial evidence, an anecdote, or both. A prospective online survey study was performed in 222 patients with psoriasis. Patients were randomized to receive clinical trial evidence of a biologic medication's efficacy and safety, an anecdote of a single patient's positive experience, or both. Responses were recorded on a 10-point Likert scale and evaluated using the Kruskal-Wallis test followed by Dunn test. Results indicated that presenting an anecdote-alone or in combination with clinical trial evidence-may be an effective way to improve patients' willingness to take a biologic medication for psoriasis.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
The Placebo Effect
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Bioequivalence studies: Biowaivers

